AU2019224694B2 - Anti-angiopoietin-2 antibodies and uses thereof - Google Patents

Anti-angiopoietin-2 antibodies and uses thereof

Info

Publication number
AU2019224694B2
AU2019224694B2 AU2019224694A AU2019224694A AU2019224694B2 AU 2019224694 B2 AU2019224694 B2 AU 2019224694B2 AU 2019224694 A AU2019224694 A AU 2019224694A AU 2019224694 A AU2019224694 A AU 2019224694A AU 2019224694 B2 AU2019224694 B2 AU 2019224694B2
Authority
AU
Australia
Prior art keywords
seq
antibody
sequence
ang2
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019224694A
Other languages
English (en)
Other versions
AU2019224694A1 (en
Inventor
Jeomil BAE
Jaeryung KIM
Mi Jeong Kim
Pilhan KIM
Gou Young Koh
Wangyuhl OH
Jang Ryul Park
Jin-Sung Park
Su Jin Seo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Advanced Institute of Science and Technology KAIST
Institute for Basic Science
Original Assignee
Korea Advanced Institute of Science and Technology KAIST
Institute for Basic Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Advanced Institute of Science and Technology KAIST, Institute for Basic Science filed Critical Korea Advanced Institute of Science and Technology KAIST
Priority claimed from PCT/KR2019/001983 external-priority patent/WO2019164219A1/en
Publication of AU2019224694A1 publication Critical patent/AU2019224694A1/en
Application granted granted Critical
Publication of AU2019224694B2 publication Critical patent/AU2019224694B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2019224694A 2018-02-20 2019-02-19 Anti-angiopoietin-2 antibodies and uses thereof Active AU2019224694B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862633038P 2018-02-20 2018-02-20
US62/633,038 2018-02-20
KR1020190018769A KR102497171B1 (ko) 2018-02-20 2019-02-18 항-안지오포이에틴-2(Ang2) 항체 및 그의 용도
KR10-2019-0018769 2019-02-18
PCT/KR2019/001983 WO2019164219A1 (en) 2018-02-20 2019-02-19 Anti-angiopoietin-2 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
AU2019224694A1 AU2019224694A1 (en) 2020-08-06
AU2019224694B2 true AU2019224694B2 (en) 2025-09-04

Family

ID=67775161

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019224694A Active AU2019224694B2 (en) 2018-02-20 2019-02-19 Anti-angiopoietin-2 antibodies and uses thereof

Country Status (8)

Country Link
US (2) US11498962B2 (https=)
EP (1) EP3755714A4 (https=)
JP (2) JP7366068B2 (https=)
KR (1) KR102497171B1 (https=)
CN (1) CN111741975B (https=)
AU (1) AU2019224694B2 (https=)
CA (1) CA3091613A1 (https=)
MX (1) MX2020008663A (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102497171B1 (ko) 2018-02-20 2023-02-08 기초과학연구원 항-안지오포이에틴-2(Ang2) 항체 및 그의 용도
KR20220002143A (ko) * 2020-06-30 2022-01-06 삼성전자주식회사 항-Ang2 항체를 포함하는 코로나바이러스 감염증을 치료하기 위한 조성물 및 그의 용도
US20230312698A1 (en) * 2020-08-07 2023-10-05 Nanjing GenScript Biotech Co., Ltd. Antibodies against human angiopoietin-2 and uses thereof
CN116209765B (zh) * 2020-08-19 2025-11-07 药物抗体公司 经修饰抗体及其制备方法
JP7749696B2 (ja) * 2021-04-23 2025-10-06 ニオテスバイオ インコーポレイテッド アンジオポエチン－２に特異的に結合する抗体、またはその断片
KR102459211B1 (ko) * 2021-04-23 2022-10-26 (주)니오테스바이오 안지오포이에틴-2에 특이적으로 결합하는 항체, 또는 이의 단편
KR20250128899A (ko) * 2024-02-20 2025-08-28 주식회사 맵틱스 Tie2 및 VEGF에 특이적으로 결합하는 이중 특이적 항체 및 이의 용도
WO2025186364A1 (en) 2024-03-06 2025-09-12 Jeansson Marie Angpt2-targeting antibodies for use in the treatment of fibrotic diseases, particularly kidney disease(s), disorder(s) or injury associated with kidney fibrosis
CN121231772B (zh) * 2025-12-02 2026-03-17 武汉市金银潭医院(武汉市传染病医院) 抗体夹心法检测猴痘病毒a29l蛋白的试剂或试剂盒及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2832746A1 (en) * 2013-07-29 2015-02-04 Samsung Electronics Co., Ltd Anti-Ang2 antibody

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7667004B2 (en) * 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
BRPI0519596B1 (pt) 2004-12-21 2022-01-18 Astrazeneca Ab Agente de ligação alvejado, anticorpo monoclonal que se liga a angiopoietina-2, molécula de ácido nucleico, vetor, e, uso do agente de ligação alvejado
US8133979B2 (en) * 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US8980268B2 (en) * 2009-07-29 2015-03-17 Regeneron Pharamceuticals, Inc. Methods for treating cancer by administering an anti-Ang-2 antibody
CA2844306C (en) 2011-08-19 2022-08-16 Regeneron Pharmaceuticals, Inc. Anti-tie2 antibodies and uses thereof
KR102146845B1 (ko) 2013-07-30 2020-08-21 삼성전자주식회사 앤지오포이에틴-2에 특이적으로 결합하는 항체 및 그의 용도
KR102196450B1 (ko) 2013-09-17 2020-12-30 삼성전자주식회사 Tie2와 결합을 유도하는 항 Ang2 항체를 포함하는 항암제
US9994632B2 (en) 2014-05-26 2018-06-12 Samsung Electronics Co., Ltd. Humanized or affinity-matured anti Ang-2 antibody and uses thereof
CA2963606A1 (en) 2014-11-10 2016-05-19 F.Hoffmann-La Roche Ag Anti-ang2 antibodies and methods of use
KR102497171B1 (ko) 2018-02-20 2023-02-08 기초과학연구원 항-안지오포이에틴-2(Ang2) 항체 및 그의 용도

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2832746A1 (en) * 2013-07-29 2015-02-04 Samsung Electronics Co., Ltd Anti-Ang2 antibody

Also Published As

Publication number Publication date
US20230272057A1 (en) 2023-08-31
MX2020008663A (es) 2021-02-09
CN111741975B (zh) 2025-02-18
CN111741975A (zh) 2020-10-02
JP2024009914A (ja) 2024-01-23
EP3755714A4 (en) 2022-02-16
KR102497171B1 (ko) 2023-02-08
CA3091613A1 (en) 2019-08-29
US12331106B2 (en) 2025-06-17
US11498962B2 (en) 2022-11-15
JP7366068B2 (ja) 2023-10-20
KR20190100060A (ko) 2019-08-28
EP3755714A1 (en) 2020-12-30
US20210079083A1 (en) 2021-03-18
AU2019224694A1 (en) 2020-08-06
JP2021514670A (ja) 2021-06-17

Similar Documents

Publication Publication Date Title
AU2019224694B2 (en) Anti-angiopoietin-2 antibodies and uses thereof
US20210238291A1 (en) Multispecific antibodies, multispecific activatable antibodies and methods of using the same
US20250011438A1 (en) Antibody Binding to Tie2 and Use Thereof
CA2955947A1 (en) Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
WO2019164219A1 (en) Anti-angiopoietin-2 antibodies and uses thereof
JP7826279B2 (ja) 抗ベータセルリン抗体、その断片、及び多重特異性結合分子
WO2022068809A1 (zh) 抗cd3抗体以及其用途
WO2022237647A1 (zh) 针对dll3的结合分子及其应用
ES2733434T3 (es) Anticuerpos anti-ROBO4
JPWO2018070390A1 (ja) 抗ｒｏｂｏ４抗体と他剤を含む組成物
CA3190173A1 (en) Anti-ang-2 antibody and use thereof
KR20240056422A (ko) 인간 안지오포이에틴-2에 특이적으로 결합하는 제1 항원 결합 부위를 포함하는 이중특이적 항체 및 그 응용
HK40130178A (en) Antibody binding to tie2 and use thereof
WO2024092263A2 (en) Anti-adam10 antibodies and uses in treatment of cancer
EA051443B1 (ru) Антитела к бетацеллюлину, их фрагменты и мультиспецифические связывающие молекулы

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)